PURPOSE: The improvement of available endovascular aortic aneurysm repair (EVAR) devices is critical for the advancement of patient care in vascular surgery. The goal of this article is to report a highly detailed, closely monitored, audited, pooled multicenter cohort of open surgical abdominal aortic aneurysm (AAA) repairs that has potential for use in future EVAR studies as a control data set. METHODS: Open surgical AAA repair data from four investigational device exemption clinical aortic endograft trials were tested for poolability, merged, and analyzed for the intervals of 0 to 30 days and 31 to 365 days. RESULTS: The data set includes 323 open patients (83% men; mean age, 70 years). Operative mortality at 30 days was 2.8%. The mean age of women was 3 years older than men, and mortality at 30 days for women was 5.7% compared with 2.2% for men (P = .18). Operative mortality for patients with large AAAs (>/=5.5 cm, 3.6%) was not different than for patients with small aneurysms (<5.5 cm, 2.4%, P = .54). All-cause mortality at 1 year was 6.7%, with significant predictors including age, sex, and renal failure. Women had 2.6-fold greater 1-year all-cause mortality rate (13.2%) than men (5.4%, P = .04), but statistical significance was lost after correction for age. Two additional AAA-related deaths occurred between days 31 and 365, resulting in a 1-year AAA-related mortality of 3.5%. CONCLUSION: This data set provides a tightly controlled, thoroughly detailed, and audited experience that has the potential to serve as an open control group for future EVAR trials.
PURPOSE: The improvement of available endovascular aortic aneurysm repair (EVAR) devices is critical for the advancement of patient care in vascular surgery. The goal of this article is to report a highly detailed, closely monitored, audited, pooled multicenter cohort of open surgical abdominal aortic aneurysm (AAA) repairs that has potential for use in future EVAR studies as a control data set. METHODS: Open surgical AAA repair data from four investigational device exemption clinical aortic endograft trials were tested for poolability, merged, and analyzed for the intervals of 0 to 30 days and 31 to 365 days. RESULTS: The data set includes 323 open patients (83% men; mean age, 70 years). Operative mortality at 30 days was 2.8%. The mean age of women was 3 years older than men, and mortality at 30 days for women was 5.7% compared with 2.2% for men (P = .18). Operative mortality for patients with large AAAs (>/=5.5 cm, 3.6%) was not different than for patients with small aneurysms (<5.5 cm, 2.4%, P = .54). All-cause mortality at 1 year was 6.7%, with significant predictors including age, sex, and renal failure. Women had 2.6-fold greater 1-year all-cause mortality rate (13.2%) than men (5.4%, P = .04), but statistical significance was lost after correction for age. Two additional AAA-related deaths occurred between days 31 and 365, resulting in a 1-year AAA-related mortality of 3.5%. CONCLUSION: This data set provides a tightly controlled, thoroughly detailed, and audited experience that has the potential to serve as an open control group for future EVAR trials.
Authors: T S Huber; J G Wang; A E Derrow; D A Dame; C K Ozaki; G B Zelenock; T C Flynn; J M Seeger Journal: J Vasc Surg Date: 2001-02 Impact factor: 4.268
Authors: Wesley S Moore; Jon S Matsumura; Michel S Makaroun; Barry T Katzen; David H Deaton; Maria Decker; Gary Walker Journal: J Vasc Surg Date: 2003-07 Impact factor: 4.268
Authors: Patrice L Anderson; Annetine Gelijns; Alan Moskowitz; Ray Arons; Lopa Gupta; Alan Weinberg; Peter L Faries; Roman Nowygrod; K Craig Kent Journal: J Vasc Surg Date: 2004-06 Impact factor: 4.268
Authors: Marc L Schermerhorn; A James O'Malley; Ami Jhaveri; Philip Cotterill; Frank Pomposelli; Bruce E Landon Journal: N Engl J Med Date: 2008-01-31 Impact factor: 91.245
Authors: Patrice L Anderson; Raymond R Arons; Alan J Moskowitz; Annetine Gelijns; Corey Magnell; Peter L Faries; Dan Clair; Roman Nowygrod; K Craig Kent Journal: J Vasc Surg Date: 2004-01 Impact factor: 4.268
Authors: Jean Jacob-Brassard; Mohammed Al-Omran; Konrad Salata; Mohamad A Hussain; Ahmed Kayssi; Graham Roche-Nagle; Charles de Mestral Journal: Can J Surg Date: 2021-03-05 Impact factor: 2.089